In this issue:
Nivolumab for advanced HCC and Child-Pugh B cirrhosis
Impact of HCC diagnosis on patients' health-related QOL
Sarcomatoid HCC: from clinical features to cancer genome
Long-term outcomes of TACE + RFA as initial early-stage HCC treatment
SITC clinical practice guideline on immunotherapies for HCC
Tremelimumab + durvalumab for unresectable HCC
Cholangiocarcinoma risk increased by persistent metabolic syndrome
Sorafenib reduces tumour growth and liver function decline in HCV-induced HCC
Association between PPI use and biliary tract cancer risk
Using distinct vascular patterns to estimate HCC survival
Please login below to download this issue (PDF)